Tags : larotrectinib

Bayer Reports Submission of MAA to the MHLW for Larotrectinib

Shots: The MAA is submission is based on P-I trial of adult patients, P-II NAVIGATE study in adult and adolescent patients and the P-I/II pediatric SCOUT study. These trials evaluate larotrectinib in 20+ histologies of solid tumors including lung, thyroid, melanoma, gastrointestinal stromal tumors, colon, cholangiocarcinoma, soft tissue sarcomas, salivary gland and infantile fibrosarcoma The […]Read More

Bayer Exercises its Exclusive WW Option to License Vitrakvi &

Shots: With the acquisition of Loxo by Eli Lilly, Bayer exercises its option and get exclusive WW rights to develop and commercialize Vitrakvi and BAY 2731954 including in the US. Loxo to receive royalties on sales of product (Ex-the US) Acc to Nov,2017 deal Bayer, and Loxo collaborated to jointly develop and commercialize larotrectinib and […]Read More